EUVIMEDEUVIMED entdecken
Crossref

Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1β release

Judith Bockstiegel, Silas L Wurnig, Jonas Engelhardt, Jana Enns, Finn K Hansen, Günther Weindl

Biochemical Pharmacology · 2023-09 · 215 · 115693

DOI: 10.1016/j.bcp.2023.115693 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2023-09. Verfasst von Judith Bockstiegel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Institute, Pharmacology and Toxicology, University of Bonn, Gerhard-Domagk-Str. 3, 53121 Bonn, Germany. Hauptthemen laut MEDLINE: Inflammasomes, NLR Family, Pyrin Domain-Containing 3 Protein. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome is an important regulator of inflammation and immune responses. Histone deacetylase 6 (HDAC6) has been implicated in the assembly and activation of the NLRP3 inflammasome in mouse cells, however, the role in human immune cells remains poorly understood. Here, we investigated the effect of HDAC6 deficiency on NLRP3-mediated interleukin (IL)-1β release using proteolysis targeting chimeras (PROTAC) technology. We designed an HDAC6 PROTAC (A6) composed of the pan-HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) and the E3 ligase ligand thalidomide and a control PROTAC (non-degrading control, nc-A6) that binds to HDAC6 but lacks the ability to induce HDAC6 degradation. A6 but not nc-A6 reduced HDAC6 levels in THP-1 macrophages without affecting cell viability. PROTAC A6 and nc-A6 significantly reduced the release of IL-1β in a concentration-dependent manner, suggesting that HDAC6 deficiency is not necessary for inhibition of NLRP3 inflammasome-mediated IL-1β release. We found that inhibition of the catalytic domain with HDAC inhibitor SAHA or the specific HDAC6 inhibitor tubastatin A is sufficient to reduce IL-1β release indicating that the enzymatic activity of HDAC6 is critical for NLRP3 inflammasome function. Mechanistically, the observed effects of HDAC6 inhibition on NLRP3-mediated inflammatory responses could be attributed to its interaction with Toll-like receptor (TLR) signaling. Tubastatin A did not affect IL-1β levels when added after TLR-mediated priming. Collectively, our findings indicate that HDAC6 inhibitors show potent anti-inflammatory activity and suppress IL-1β release by human macrophages, independent of NLRP3 assembly and activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinHumansAnimalsMiceHistone Deacetylase 6Histone Deacetylase InhibitorsCarrier ProteinsToll-Like ReceptorsInterleukin-1betaCaspase 1Hydroxamic AcidsIndoles

Stichwörter der Autor:innen

HDAC6 inhibitorsHuman macrophagesIL-1betaNLRP3 inflammasomePROTACsSAHA

Substanzen

InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinHistone Deacetylase 6Histone Deacetylase InhibitorsCarrier ProteinsToll-Like ReceptorsInterleukin-1betaCaspase 1tubastatin AHydroxamic Acids

Autor:innen und Institutionen

  • Pharmaceutical Institute, Pharmacology and Toxicology, University of Bonn, Gerhard-Domagk-Str. 3, 53121 Bonn, Germany.
  • Pharmaceutical Institute, Pharmaceutical and Cell Biological Chemistry, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany.
  • Pharmaceutical Institute, Pharmacology and Toxicology, University of Bonn, Gerhard-Domagk-Str. 3, 53121 Bonn, Germany. Electronic address: guenther.weindl@uni-bonn.de.

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Bockstiegel, J., Wurnig, S. L., Engelhardt, J., Enns, J., Hansen, F. K., & Weindl, G. (2023). Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1β release. Biochemical Pharmacology, 215, 115693. https://doi.org/10.1016/j.bcp.2023.115693

Vancouver

Bockstiegel J, Wurnig SL, Engelhardt J, Enns J, Hansen FK, Weindl G. Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1β release. Biochemical Pharmacology. 2023;215:115693. doi:10.1016/j.bcp.2023.115693

BibTeX
@article{Bockstiegel2023,
  author = {Bockstiegel, Judith and Wurnig, Silas L and Engelhardt, Jonas and Enns, Jana and Hansen, Finn K and Weindl, Günther},
  title = {Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1β release},
  journal = {Biochemical Pharmacology},
  year = {2023},
  volume = {215},
  pages = {115693},
  doi = {10.1016/j.bcp.2023.115693}
}
Kostenlos starten →